INS and Hypoglycemia: This meta-analysis was undertaken using data from seven randomized controlled trials (RCTs) of patients with type 2 diabetes treated with insulin lispro to test the hypothesis that the use of insulin lispro in patients ≥65 years of age is as safe and efficacious to use as it is in patients <65 years of age, as measured by change in HbA1c and rates of hypoglycemia.